Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios Tsianakas

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Journal of the American Academy of Dermatology|November 29, 2025
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trialAthanasios Tsianakas, Thierry Passeron, Nina Magnolo, et al.
The British Journal of Dermatology|September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 4, 2014
Immune suppression via glucocorticoid-stimulated monocytes: a novel mechanism to cope with inflammationGeorg Varga, Jan Ehrchen, Anne Brockhausen, et al.
Dermatology and Therapy|December 14, 2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front LineBruce Strober, Joyce Leman, Maja Mockenhaupt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutionsThomas K Eigentler, Max Schlaak, Jessica C Hassel, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 7, 2020
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell LymphomaPierluigi Porcu, Stacie Hudgens, Steven Horwitz, et al.
Acta Dermato-Venereologica|June 11, 2026
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisAndreas Wollenberg, Jonathan I Silverberg, Franz J Legat, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.
JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 8, 2021
Documentation of psoriasis in routine care - expert consensus on a German data setMarina Otten, Ulrich Mrowietz, Ralph Michael von Kiedrowski, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Journal of the American Academy of Dermatology|November 29, 2025
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trialAthanasios Tsianakas, Thierry Passeron, Nina Magnolo, et al.
The British Journal of Dermatology|September 23, 2025
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)Richard B Warren, Marjolein de Bruin-Weller, Athanasios Tsianakas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 4, 2014
Immune suppression via glucocorticoid-stimulated monocytes: a novel mechanism to cope with inflammationGeorg Varga, Jan Ehrchen, Anne Brockhausen, et al.
Dermatology and Therapy|December 14, 2021
Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front LineBruce Strober, Joyce Leman, Maja Mockenhaupt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 31, 2014
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutionsThomas K Eigentler, Max Schlaak, Jessica C Hassel, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 7, 2020
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell LymphomaPierluigi Porcu, Stacie Hudgens, Steven Horwitz, et al.
Acta Dermato-Venereologica|June 11, 2026
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic DermatitisAndreas Wollenberg, Jonathan I Silverberg, Franz J Legat, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.
JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 8, 2021
Documentation of psoriasis in routine care - expert consensus on a German data setMarina Otten, Ulrich Mrowietz, Ralph Michael von Kiedrowski, et al.
Pageof 7